Aims: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce several cardiovascular risk factors, including plasma glucose, blood pressure, albuminuria and body weight. Long-term treatment lowers risks of cardiovascular and renal events. The objective of this post hoc analysis was to determine the effects of canagliflozin treatment versus placebo on clinical outcomes in relation to body mass index (BMI).
| INTRODUCTION
Both type 2 diabetes and obesity are epidemics causing major global public health problems. 1 Excess body fat is a major contributor to the development of type 2 diabetes, as well as cardiovascular (CV) disease and premature death. [2] [3] [4] [5] [6] [7] [8] Given the benefits of weight loss in the prevention and treatment of type 2 diabetes, 9, 10 weight management is recommended for patients with type 2 diabetes who are overweight or obese. 11 One of the more important considerations in deciding on an appropriate antihyperglycaemic agent is its effects on body weight. 11 Sodium glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose levels by reducing the renal threshold for glucose and increasing urinary glucose excretion. 12 In addition, SGLT2 inhibitors improve other CV risk factors, including blood pressure (BP), albuminuria and body weight. Reductions in body weight may be achieved both through loss of calories and through natriuresis. Moderate and sustained reductions in body weight were observed in the EMPA-REG OUTCOME trial, 13, 14 the CANVAS (CANagliflozin cardioVascular Assessment Study) Program 15, 16 and the DECLARE-TIMI 58 trial. 17 The same trials demonstrated that SGLT2 inhibitors reduced the risk of CV and renal events. However, whether the effects of SGLT2 inhibitors on weight loss vary according to participant characteristics and whether the benefits of SGLT2 inhibitors differ among patients with differences in body mass index (BMI) are unknown.
The objectives of this post hoc analysis were to determine whether the effects of the SGLT2 inhibitor canagliflozin on CV outcomes, renal outcomes, body weight and safety indicators vary according to baseline BMI levels, using data from the CANVAS Program.
| MATERIALS AND METHODS

| Ethics
CANVAS and CANVAS-Renal (CANVAS-R; ClinicalTrials.gov registration numbers NCT01032629 and NCT01989754) were approved by the institutional review board for each centre, and all participants provided written informed consent. All procedures followed were in accordance with the Declaration of Helsinki 1964, as revised in 2013.
| Study design and participants
The CANVAS Program, comprising two similarly designed and conducted large-scale double-blind trials, CANVAS and CANVAS-R, assessed the CV and renal efficacy and safety of canagliflozin compared with placebo. A detailed description of the design and the main results of the CANVAS Program were previously published. 15, 18 In brief, 10 142 participants with type 2 diabetes and a history or high risk of CV disease were enrolled from 667 centres in 30 countries. The individuals included men and women with type 2 diabetes [haemoglobin A1c (HbA1c) ≥7.0% and ≤10.5%] who were either ≥30 years of age with a history of symptomatic atherosclerotic CV disease or ≥50 years of age with ≥2 of the following risk factors for CV disease: duration of diabetes mellitus ≥10 years, systolic BP >140 mmHg while receiving ≥1 antihypertensive agents, current smoking, microalbuminuria or macroalbuminuria or high-density lipoprotein cholesterol <1 mmol/L. Participants were required to have an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m 2 at entry, but there were no specific body weight-related inclusion criteria.
| Randomized treatment and follow-up
After a 2-week, single-blind, placebo run-in period, participants in CAN-VAS were randomly assigned in a 1:1:1 ratio to receive once-daily canagliflozin 100 mg, canagliflozin 300 mg or placebo, while participants in CANVAS-R were randomly assigned in a 1:1 ratio to receive once-daily canagliflozin 100 mg or matching placebo, with an optional uptitration to 300 mg starting at week 13, through a central web-based system with the use of a computer-generated randomization schedule with randomly permuted blocks. Participants were required to have stable background glucose-lowering therapy for 8 weeks before screening and wherever possible to persist with this treatment regimen unchanged for the first 18 weeks after randomization in CANVAS. 19 Beyond 18 weeks in CAN-VAS and throughout CANVAS-R, background drug treatments for glucose control were at the discretion of the responsible investigator, with the exception of SGLT2 inhibitors. 19, 20 All participants and trial staff were blinded to individual treatment allocations until the end of the trial.
Participants were followed at least three times in the first year and at 6-month intervals thereafter until the end of the study, with telephone follow-up between face-to-face assessments.
| Body mass index
BMI was calculated from height and body weight. For this analysis, participants were classified into three groups based on BMI at baseline: <25, 25-<30 and ≥30 kg/m 2 . Only participants with baseline BMI measurements were included in this analysis.
| Outcomes
The primary outcome for the CANVAS Program was a composite of death from CV causes, non-fatal myocardial infarction (MI) or non-fatal stroke. Secondary outcomes included death from CV causes, fatal or non-fatal MI, fatal or non-fatal stroke, hospitalization for heart failure and a composite renal outcome of 40% decrease in eGFR, end-stage kidney disease or renal death. This analysis also assessed effects on the intermediate outcomes, including HbA1c, systolic BP, body weight, urine albumin/creatinine ratio (UACR) and eGFR. In addition, the effects on key safety outcomes were determined. Safety outcomes included adverse events coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) at the time of the database lock. 15 Both serious and non-serious adverse events were collected for the CANVAS trial until early 2014, as mandated by the US Food and Drug Administration and other regulatory bodies for initial approval of canagliflozin. Thereafter, following registration of the drug, only serious adverse events, adverse events leading to study drug discontinuation, and selected adverse events of interest were collected across the CANVAS Program.
All major CV, renal and selected safety outcomes were adjudicated by central endpoint adjudication committees blinded to treatment allocation.
Detailed definitions for the outcomes were previously published. 15 
| Statistical methods
Differences in baseline characteristics across BMI categories were tested by linear regression analysis or logistic regression analysis, as appropriate. Cox regression models were used to estimate hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs)
for the primary and other CV and renal outcomes, with stratification according to trial and history of CV disease (for CV outcomes) and baseline eGFR level (<60 or ≥60 mL/min/1.73 m 2 ) as the exploratory variable (for the main renal outcome) using an intention-to-treat approach, for all canagliflozin groups combined versus placebo. Safety outcomes were analysed using an on-treatment approach (with data based on participants who had a safety outcome while they were receiving study drug, or within 30 days after discontinuation of study . Absolute risk reductions for CV and renal outcomes were also similar across BMI subgroups (P for heterogeneity ≥0.09; Figure 1 ).
| Intermediate markers
Irrespective of BMI, canagliflozin compared with placebo decreased HbA1c, systolic BP, UACR and eGFR. The placebo-subtracted mean differences in these intermediate markers were constant across BMI subgroups (all P for heterogeneity ≥0.09), except for body weight, where a greater absolute reduction in weight was observed among those with baseline BMI ≥30 kg/m 2 (P for heterogeneity <0.001; Figure 2 ). There were, however, no differences in effects across BMI subgroups if percentage weight loss was assessed (P for heterogeneity = 0.17). 
| Safety outcomes
The effects of canagliflozin on safety outcomes are shown in Figure 3 and Figure S2 (see Supporting Information). The risks of adverse events were consistent across the subgroups defined by baseline BMI (P for heterogeneity ≥0.15) with the exception of urinary tract infection (P for heterogeneity = 0.01), the risk for which appeared greater among patients with baseline BMI 25-<30 kg/m 2 but not among patients with baseline BMI <25 or ≥30 kg/m 2 . This heterogeneity was not observed in the analyses using BMI as a continuous variable (P for interaction = 0.83).
| DISCUSSION
In this large-scale randomized, controlled trial of patients with type 2 diabetes, reductions in the risks of CV and renal events achieved with canagliflozin were consistent across subgroups defined by baseline BMI levels of <25, 25-<30 and ≥30 kg/m 2 . Effects of canagliflozin on safety outcomes were also broadly similar across these subgroups. Overall, our findings suggest that CV and renal protective benefits of canagliflozin are not modified by baseline BMI levels, and further highlight the value of this therapy for CV disease prevention among obese, overweight and leaner patients.
Higher BMI is associated with increased levels of circulating free fatty acids and greater accumulations of harmful visceral, hepatic, skeletal, intracardial and epicardial fat. [21] [22] [23] In particular, epicardial adipose tissue surrounding the heart generates pathogenic mechanical, endocrinological, immunological, paracrine and vasocrine signalling, all of which may contribute to heart failure-particularly heart failure with preserved ejection fraction. 24 Individuals with diabetes and higher baseline BMI may also have greater sodium and fluid retention and might achieve enhanced protection from SGLT2 inhibitor therapy because of the known natriuretic effects of the class. Therefore, there was a rationale for anticipating potentially greater effects of canagliflozin on clinical outcomes among patients with higher BMI at baseline.
The CANVAS Program findings of comparable effectiveness of SGLT2 inhibition for the prevention of CV and renal outcomes across BMI subgroups align with similar observations from the EMPA-REG OUTCOME trial 13 Weight loss due to glycosuria is a unique characteristic of SGLT2 inhibitors 27 and, although not previously identified as a strong independent mediator of CV protection, 28 is clearly viewed as an important benefit by both patients and clinicians. 29 These analyses identified that percentage reductions in body weight with canagliflozin therapy were consistent across different initial levels of BMI. Greater weight loss was associated with several patient characteristics, including absence of a history of heart failure or hypertension, use of insulin, use of GLP-1 agonist and non-use of a sulphonylurea, but the mechanism for the greater percentage reduction in weight loss in these patients was not apparent. Similarly unclear was the reason why weight reductions in this study and a previous report 30 were greater among those with lower baseline HbA1c levels at 3 months-the opposite might have been anticipated, as renal excretion of glucose and calories with SGLT2 inhibition would be lower among those with well-controlled glycaemia. 31 The observed differences in weight reduction between eGFR subgroups were not linearly associated with renal function as might have been expected. 27 The greater effect of canagliflozin on weight at 12 months versus at 3 months probably reflects dual mechanisms of weight loss that are additive over time. Early reductions in body weight are likely to be driven primarily by fluid excretion resulting from the known natriuretic effects of the compound, with subsequent additional reduction in body weight attributable mostly to caloric loss and associated reduction in fat mass. 32 The strengths of this analysis include the large and diverse patient population derived from an international, multicentre randomized trial conducted to a high standard, with a long duration of follow-up and rigorous adjudication of the main outcomes. It is of note that the con- We report these findings on behalf of the CANVAS Program Collaborative Group. We thank all investigators, study teams and patients for participating in these studies. Medical writing support was provided by Corporation; and receiving lecture fees from Janssen, with any consultancy, honoraria or travel support paid to his institution.
ORCID
Toshiaki Ohkuma https://orcid.org/0000-0001-8105-7102
David R. Matthews https://orcid.org/0000-0001-6504-0036
Bruce Neal https://orcid.org/0000-0002-0490-7465
